@Article{or.2026.074078,
AUTHOR = {Aleksander Strąk, Ludmiła Grzybowska-Szatkowska, Paweł Cisek, Marta Ostrowska-Leśko, Jarosław Dudka, Joanna Kubik, Jacek Osuchowski, Paweł Szmygin, Bożena Jarosz, Andrzej Krajka, Tomasz Krajka, Kazimierz Szatkowski, Brygida Ślaska},
TITLE = {MYO18A Expression is a Prognostic Factor for Progression-Free Survival in Grade 4 Adult gliomas. Preliminary Report},
JOURNAL = {Oncology Research},
VOLUME = {34},
YEAR = {2026},
NUMBER = {5},
PAGES = {--},
URL = {http://www.techscience.com/or/v34n5/67049},
ISSN = {1555-3906},
ABSTRACT = { <b>Objectives:</b> Brain gliomas are among the tumors with the worst prognosis, and their incidence is increasing. Postoperative temozolomide-based chemoradiotherapy for grades 3 and 4 gliomas extended overall survival (OS) by approximately two months. An increasing number of clinical trials are investigating molecular-based therapy. Recent studies have demonstrated the involvement of Golgi apparatus proteins, including MYO18A (myosin-18A), in processes associated with abnormal proliferation, migration, apoptosis evasion, and angiogenesis promotion. The aim of this study was to investigate whether MYO18A has prognostic value in patients treated for brain gliomas. <b>Methods:</b> The research material in the work included tumor samples taken during neurosurgery and blood samples from 45 patients treated for brain gliomas with grade of 1 to 4 according to WHO, which were used to determine the expression of <i>MYO18A</i> mRNA (messenger ribonucleic acid). Expression of <i>MYO18A</i> was presented as fold changes in RQ (relative quantification) mRNA levels. <b>Results:</b> This study showed higher <i>MYO18A</i> values in patients diagnosed with grade G4 glioma among those with a shorter progression-free survival (PFS) time and those living shorter than the group average. However, statistically significant differences were achieved only for PFS for the <i>MYO18A</i> RQ feature (PFS = 4.64, SD = 2.16 vs. PFS = 15.83 and SD = 7.27, <i>p</i> = 0.0231). Also, a positive correlation was demonstrated between tumor volume and <i>MYO18A</i> expression. <b>Conclusion:</b> The level of expression of <i>MYO18A</i> can be considered a prognostic factor for PFS in patients treated for G4 gliomas, because higher <i>MYO18A</i> expression was associated with earlier recurrence.},
DOI = {10.32604/or.2026.074078}
}